Investigating the impact of Crohn’s Disease on the bioaccessibility of a lipid-based formulation with an in vitro dynamic gastrointestinal model

Angela Effinger; Mark McAllister; Irena Tomaszewska; Caitriona O'Driscoll; Mark Taylor; Steve Gomersall; James Heaton; Kieran L  Smith; Inese Sarcevica; Sam L Young; Nikoletta Fotaki

Investigating the impact of Crohn’s Disease on the bioaccessibility of a lipid-based formulation with an in vitro dynamic gastrointestinal model

Angela Effinger
, Mark McAllister
, Irena Tomaszewska
, Caitriona O'Driscoll
, Mark Taylor
, Steve Gomersall
, James Heaton
, Kieran L Smith
, Inese Sarcevica
, Sam L Young
, Nikoletta Fotaki

School of Pharmacy

Pfizer
University of Bath, Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English (Ireland)
Pages (from-to)	1530-1543
Journal	Molecular Pharmaceutics
Volume	18
Issue number	4
Publication status	Published - 2021

Cite this

@article{57fc69bfbbe44a12a582377b2d7e8178,

title = "Investigating the impact of Crohn{\textquoteright}s Disease on the bioaccessibility of a lipid-based formulation with an in vitro dynamic gastrointestinal model",

author = "Angela Effinger and Mark McAllister and Irena Tomaszewska and Caitriona O'Driscoll and Mark Taylor and Steve Gomersall and James Heaton and Smith, \{Kieran L\} and Inese Sarcevica and Young, \{Sam L\} and Nikoletta Fotaki",

year = "2021",

language = "English (Ireland)",

volume = "18",

pages = "1530--1543",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

number = "4",

}

TY - JOUR

T1 - Investigating the impact of Crohn’s Disease on the bioaccessibility of a lipid-based formulation with an in vitro dynamic gastrointestinal model

AU - Effinger, Angela

AU - McAllister, Mark

AU - Tomaszewska, Irena

AU - O'Driscoll, Caitriona

AU - Taylor, Mark

AU - Gomersall, Steve

AU - Heaton, James

AU - Smith, Kieran L

AU - Sarcevica, Inese

AU - Young, Sam L

AU - Fotaki, Nikoletta

PY - 2021

Y1 - 2021

M3 - Article

SN - 1543-8384

VL - 18

SP - 1530

EP - 1543

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

IS - 4

ER -